<DOC>
	<DOC>NCT01732757</DOC>
	<brief_summary>This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Alcaftadine</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>History of ocular allergies within the past 24 months. Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period. Any presence of active ocular infection or history of an ocular herpetic infection. Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months. Have any planned surgery during the study or 30 days after the study.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>